MedTrace Logo

Addition of Everolimus to Standard of Care in Carcinoma Gallbladder

NCT05833815 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2024-08-13

No results posted yet for this study

Summary

Gallbladder cancer (GBC) is the most common malignant tumour of the biliary tract. It is also the most aggressive cancer of the biliary tract with the shortest median survival from the time of diagnosis. Currently, radical resection is the most effective strategy to potentially cure GBC. Chemotherapy and radiotherapy have been employed as adjuvant and palliative setting, however, the overall survival is still dismal. This study aim to evaluate the addition of Everolimus in addition to standard of care in gallbladder cancer.

Conditions

  • Gallbladder Cancer

Interventions

DRUG

Everolimus 10 mg

Oral Everolimus 10 mg daily in addition to standard of care i.e. GemOx or CapOx

DRUG

Standard of care

GemOx or CapOx

Sponsors & Collaborators

  • Banaras Hindu University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2024-12-30
Completion
2024-12-30

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05833815 on ClinicalTrials.gov